¹ØÓÚÂØ¿¨Ä¹ÑÓ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆµÄ˵Ã÷

ÓɽðÔó´óѧµÄҽѧ¡¢ÖÆÒ©ºÍ½¡¿µ¿ÆÑ§Ñо¿ËùKenjiro Ono£¨Ð¡Ò°ÏͶþÀÉ£©½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÓëng28ÄϹ¬Öêʽ»áÉçÏàÖú £¬ÀûÓÃпª·¢µÄÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×-¦ÂÔ­ÏËά£¨Lec-PF£©ÕÉÁ¿ÏµÍ³Ö¤Ã÷ £¬Óë·Ç°¢¶û´Äº£Ä¬²¡±ÈÕÕ×éÏà±È £¬°¢¶û´Äº£Ä¬²¡»¼Õß´ÓÇá¶ÈÈÏÖªÕϰ­µ½Çá¶ÈºÍÖØ¶È³Õ´ôµÄ¸÷¸ö½×¶ÎÄÔ¼¹ÒºÖеÄLec-PFŨ¶È¶¼ÓÐËùÉý¸ß¡£±ðµÄ £¬ÕâÏîÑо¿»¹·¢Ã÷ £¬ÄÔ¼¹ÒºÖÐ Lec-PFµÄŨ¶ÈÓë·´Ó¦Éñ¾­±äÐÔµÄÉúÎï±ê¼ÇÎïÓÐÃ÷ÏÔµÄÏà¹ØÐÔ¡£

ÂØ¿¨Ä¹ÊÇÒ»ÖÖÆæÌصÄË«ÖØ×÷Óÿ¹Ìå £¬³ýÁËÇå³ý°ß¿éÍâ £¬»¹Ñ¡ÔñÐÔ½áºÏµí·ÛÑùÂѰ×-¦ÂÔ­ÏËά£¨PF£© £¬ÊÇÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆÎªÔçÆÚAD£©»¼ÕßµÄÒ»ÖÖÒ©Îï¡£ÕâÏîÑо¿µÄ½á¹û±êÃ÷ £¬ÂØ¿¨Ä¹²¶»ñµÄPF£¨Lec-PF£©±£´æÓÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÄÔ¼¹ÒºÖÐ £¬Lec-PFÊÇÒ»Ö־綾µÄ²¡ÀíÂѰ× £¬»áµ¼ÖÂÉñ¾­ÍËÐÐÐԱ䡣ÕâÏîÑо¿½ÒʾÁËÂØ¿¨Ä¹¼õ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆ¡£

»ùÓÚÕâЩ·¢Ã÷ £¬Î´À´¿ÉÄÜÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿ÄÔ¼¹ÒºÖÐLec PFµÄŨ¶È £¬ÒÔÆÀ¹ÀÖÎÁÆÐ§¹û¡£±ðµÄ £¬ÓÉÓÚÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׵ÈÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø £¬Ô¤¼ÆÕâЩ·¢Ã÷Ò²¿ÉÓÃÓÚÔ¤²â°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÔ¤ºó¡£

ÕâÏîÑо¿ÓÚ2025Äê1ÔÂ6ÈÕ18:30£¨ÃÀ¹ú¶«²¿±ê׼ʱ¼ä£©Ðû²¼ÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶Annals of Neurology¡·µÄÍøÂç°æÉÏ¡£

Ñо¿Åä¾°ºÍÄ¿µÄ

µí·ÛÑùÂѰ׼¶Áª¼Ù˵ÊǹØÓÚAD²¡ÒòµÄÖ÷ÒªÀíÂÛ £¬¸Ã¼Ù˵ÈÏΪ¦Âµí·ÛÑùÂѰף¨A¦Â£©ÔÚÉñ¾­ÔªÍâÒì³£¾Û¼¯ £¬ËæºóÐγÉtauÉñ¾­Ô­ÏËά²ø½á £¬¶ÔÉñ¾­ÔªÔì³ÉËðÉË £¬²¢µ¼Ö¼²²¡±¬·¢¡£Ô­ÏËάÐÎ̬µÄ¦Âµí·ÛÑùÂѰױÈÏËάºÍ°ß¿éÐÎ̬¸ü¾ßÉñ¾­¶¾ÐÔ £¬ºóÕßÊÇÒì³£¾Û¼¯A¦ÂµÄ×îºó½×¶Î £¬Òò´ËÈÏΪPF¿ÉÄܻᵼÖÂÉñ¾­ÍËÐÐÐԱ䣨²Î¿¼ÎÄÏ×£ºAmin LºÍHarris DA.2012£©¡£ÂØ¿¨Ä¹ÊÇÒ»ÖÖ¿¹µí·ÛÑùÂѰ×-¦ÂÔ­ÏËά¿¹Ìå £¬×Ô2023ÄêÒÔÀ´Ò»Ö±ÓÃÓÚÖÎÁÆÔçÆÚAD¡£È»¶ø £¬´ËǰûÓйØÓÚÕÉÁ¿ÈËÀàÉúÎïÑù±¾ÖÐPFŨ¶ÈµÄ±¨¸æ £¬²¢ÇÒ×÷ÎªÂØ¿¨Ä¹ÖÎÁưеãµÄPFÔÚÕû¸öADÁ¬ÐøÌåÖеÄÂþÑÜÇé¿öÉв»Çå³þ¡£

ÔÚÕâÏîÑо¿ÖÐ £¬Ñо¿Ð¡×éʹÓÃпª·¢µÄ¸ßÁéÃô¶ÈLec-PFÕÉÁ¿ÏµÍ³ £¬ÕÉÁ¿ÁËÁÙ´²Ç°AD¡¢ADÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍAD³Õ´ôÊÜÊÔÕßÒÔ¼°SNAP£¨ÒÉËÆ·ÇAD²¡ÀíÉúÀíѧ£©»¼ÕߺÍÈÏÖª¹¦Ð§Õý³£ÕßµÄÈËÄÔ¼¹Òº£¨CSF£©ÖÐLec-PFµÄŨ¶È £¬²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42Á׵ĹØÏµ¡¢ ²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42¡¢Á×Ëữtau£¨p-tau£©181£¨*9£©¡¢p-tau 217¡¢×ÜtauºÍÉñ¾­Á£ÂѰ×Ö®¼äµÄ¹ØÏµ¡£

Ñо¿½á¹û×ÛÊö

ADÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­»ò³Õ´ô»¼Õߣ¨Í¼1ÖеÄMCI+¡¢AD+×飩µÄLec PF CSFŨ¶ÈÃ÷ÏÔ¸ßÓÚÈÏÖª¹¦Ð§Õý³£µÄ»¼Õߣ¨Í¼ÖеÄYNCºÍAMC×飩¡£

¶ÔÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓëÆäËûÄÔ¼¹Òº±ê¼ÇÎA¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×Ütau¡¢Éñ¾­¿ÅÁ£ÂѰף©Ö®¼ä½øÐÐÁËÏà¹ØÐÔÆÊÎö¡£Í¼2ÏÔʾÁËLec PFºÍÖÖÖÖCSF±ê¼ÇÎïÖ®¼äµÄSpearmanÏà¹ØÏµÊý£¨95%ÖÃÐÅÇø¼ä£©¡£ÔÚËùÓÐÊÜÊÔÕßÖУ¨Í¼2ÖеĺÚÏߣ© £¬ÄÔ¼¹ÒºÖÐLec PFŨ¶ÈÓëa¦Â42¡¢a¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׳ÊÏà¹ØÐÔ £¬SpearmanϵÊýΪ0.2»ò¸ü¸ß¡£ÖµµÃ×¢ÒâµÄÊÇ £¬µ±½ö¹Ø×¢A¦ÂÑôÐÔ×éʱ£¨Í¼2ÖеĺìÏߣ© £¬Lec PFÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰף¨A¦Â¼¶ÁªÖÐA¦ÂÏÂÓεÄÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎÌåÏÖ³öºÜÇ¿µÄÏà¹ØÐÔ£¨SpearmanϵÊýΪ0.4»ò¸ü¸ß£© £¬ÕâÊÇADµÄ²¡Àíѧ¸Ä±ä £¬±êÃ÷Lec PFÊÇÒ»ÖÖÓëÉñ¾­ÍËÐÐÐÔ¼²²¡Ïà¹ØµÄ¾ç¶¾²¡ÀíÂѰס£

δÀ´Éú³¤

ÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿CSFÖеÄLec-PFŨ¶È¿ÉÄÜÓÐÖúÓÚÆÀ¹ÀÂØ¿¨Ä¹ÖÎÁƵÄÁÆÐ§¡£±ðµÄ £¬ÓÉÓÚCSFÖÐLec-PFµÄŨ¶ÈÓëÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø £¬Òò´ËËüÒ²¿ÉÄÜÓÐÖúÓÚÔ¤²âAD»¼ÕßµÄÔ¤ºó¡£

±¾Ñо¿»ñµÃÁËÈÕ±¾Ò½Ñ§Ñо¿¿ª·¢»ú¹¹£¨AMED£©³Õ´ôÖ¢Ñо¿ÓëÉú³¤×ÊÖú£¨×ÊÖúºÅ22dk0207053£©¡¢×ªÐÍÑо¿×ÊÖú£¨×ÊÖú±àºÅ23H03850£©ºÍ¿ÆÑ§Ñо¿×ÊÖú£¨Åú×¼ºÅJP19k07965¡¢JP22k07514£©µÈÏîÄ¿µÄÖ§³Ö¡£

ͼ 1 ƾ¾ÝÁÙ´²Õï¶ÏºÍµí·ÛÑùÂѰ×ÑôÐÔ/ÒõÐÔ·ÖÀàµÄÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×Ô­ÏËά£¨CSF Lec-PF£©Å¨¶È

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ͼ 1 ˵Ã÷

·½¿òͼÖеķ½¿òÌåÏÖËÄ·ÖλÊý¼ä¾à £¬Ë®Æ½ÏßÌåÏÖÖÐλÊý¡£¸÷×éËõд£º YNC£¨ÄêÇáÕý³£±ÈÕÕ×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢AMC£¨ÄêÁ䯥Åä±ÈÕÕ×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢CI-£¨ÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢CU+£¨ÈÏÖª¹¦Ð§Î´ÊÜËð×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢MCI+£¨Çá¶ÈÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢AD+£¨AD ³Õ´ô×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢CSF£¨ÄÔ¼¹Òº£©¡£

*p < 0.05

ͼ 2 ÄÔ¼¹Òº±ê¼ÇÎïÓëÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×Ô­ÏËά£¨CSF Lec-PF£©µÄÏà¹ØÐÔ

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ͼ2˵Ã÷

ºÚÏߺͺìÏß»®·ÖÌåÏÖÕû¸öÊÜÊÔÕß×éºÍµí·ÛÑùÂѰ×ÑôÐÔÊÜÊÔÕß×éCSF Lec-PFÓë¸÷ÄÔ¼¹Òº±ê¼ÇÎïÖ®¼ä˹Ƥ¶ûÂüÏà¹ØÏµÊýµÄ95%ÖÃÐÅÇø¼ä (CI)¡£ºÚµãºÍºìµãÌåÏÖ˹Ƥ¶ûÂüÏà¹ØÏµÊýµÄÖÐÖµ¡£ºÚÏߺͺìÏßÖ®¼äµÄ¾Þ´ó²î±ð·´Ó¦ÁËA¦Â ÑôÐÔ»òÒõÐÔ״̬µÄÏÔÖøÓ°Ïì¡£

ÔÚÕâÏîÆÊÎöÖÐ £¬ËùÓÐÊÜÊÔÕߣ¨ºÚÏߣ©µÄCSF Lec-PFÓëËùÓвⶨµÄÉúÎï±ê¼ÇÎ¼´A¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau 217¡¢×Ü-tauºÍÉñ¾­¿ÅÁ£ÂѰף©Ö®¼äµÄÏà¹ØÏµÊý¾ùΪ0.2»ò¸ü¸ß £¬±êÃ÷ CSF Lec-PF ÓëÕâЩÉúÎï±ê¼ÇÎïÖ®¼ä±£´æÏÔÖøÏà¹ØÐÔ¡£ÔÚµí·ÛÑùÂѰ×ÑôÐÔ×飨ºìÏߣ©ÖÐ £¬CSF Lec-PFÓëCSF total-tauµÄSpearmanÏà¹ØÏµÊý»®·ÖΪ0.634£¨CI£º0.409-0.786£© £¬CSF Lec-PFÓëCSF neurograninµÄSpearmanÏà¹ØÏµÊý»®·ÖΪ0.434£¨CI£º0.260-0.581£© £¬±êÃ÷CSF Lec-PFÓëÕâÁ½ÖÖÉúÎï±ê¼ÇÎïÖ®¼ä±£´æºÜÇ¿µÄÏà¹ØÐÔ¡£ÁíÒ»·½Ãæ £¬CSF Lec-PFÓëÄÔA¦ÂÀÛ»ýÉúÎï±ê¼ÇÎïCSF A¦Â42ºÍCSF A¦Â42/40±ÈÖµÖ®¼äµÄÏà¹ØÐÔ¶¼Ïà¶Ô½ÏµÍ¡£Õâ±êÃ÷ £¬CSF Lec-PFµÄº¬Á¿ÓëÉñ¾­ÍËÐÐÐÔ±äµÄ¹ØÏµ±È´óÄÔÖÐA¦ÂµÄ»ýÀÛ¸üΪÃÜÇС£

 

ÎÄÕ·¢ÐÄÇé¿ö£º

ÆÚ¿¯Ãû³Æ£ºAnnals of Neurology

ÎÄÕÂÌâÄ¿: Lecanemab-associated amyloid-¦Â protofibril in cerebrospinal fluid correlates with

biomarkers of neurodegeneration in Alzheimer¡¯s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)

×÷Õß: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono

Ðû²¼ÈÕÆÚ£ºJanuary 6, 2025 (US Eastern Standard Time).

DOI: 10.1002/ANA.27175

 

ÐÅÏ¢ÁªÂ磺

¡ö Regarding research content

Kanazawa University

Professor Kenjiro Ono

TEL: +81-(0)76-265-2292

Email: onoken@med.kanazawa-u.ac.jp

Associate Professor Moeko Shinohara

TEL: +81-(0)76-265-2292

Email: m-nohara@med.kanazawa-u.ac.jp

Eisai Co., Ltd.

Kanta Horie

E-mail: kanta_horie@eisai.com

¡ö Public Relations Officer

General Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences

Administration Department, Kanazawa University

Rina Yamada

TEL: +81-(0)76-265-2109

E-mail: t-isomu@adm.kanazawa-u.ac.jp

Eisai Co., Ltd. PR Department

TEL: +81-(0)3-3817-5120

±àºÅ£ºECN2025-0002